# Tianchen Biological

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianchen-biological

- Industry: Biotechnology
- Headquarters: Changshu, China
- Website: www.longbio.com
- Total disclosed funding: $43M
- Latest round: Series C (Jun 3, 2025)
- Investors on record: 14

## About

Established in 2020 and based in Suzhou, China, Tianchen Biological is a biomedical company that specializes in the research and development of differentiated macromolecular antibodies in the field of autoimmune diseases. In March 2021, the company's products LP-003 and LP-001 received clinical approval from the State Drug Administration. Dr. Niachao Sun of the company, is the founder of Tanox, USA, and Dr. Heng Liu graduated from the State University of New York with a Ph.D. in Biology. The company has cooperated with RxVision. The company also established a research and development center in Shanghai. In October 2023, it raised over CNY 100 million in series B funding from new investors Changshu Kaisheng Equity Investment Fund, Hefei Ruicheng Venture Capital Management, Oriental Fortune Capital, Shanghai Tongrui Investment Management and Shanzheng Innovation Investment. In June 2025, Tianchen Biological raised an undisclosed amount of series C funding co-led by new investor HighLight Capital and returning investor Qiming Venture Partners, with participation from other new investors Linchuang Capital, Beida Fund, Sanyi Capital, Shanzheng Innovation Investmen, TruMed Healthcare, and other undisclosed investors. The technology platforms developed by the company include antibody discovery platform, antibody engineering platform and process development platform. Antibody engineering platform includes the modification of recoverable antibodies, modification of CHO display platform and other functions. The pipelines of the company include LP-003, LP-001, LP-005, LP-006, and other pipelines, which can be used in ophthalmology, nephrology, hematology. The company also provides antibody testing services. The company’s revenue is generated by providing large molecule antibodies. The company will use the funding to advance clinical research of core projects in China, accelerate product launches and expand into the international market.

## Funding rounds

- Series C, Jun 3, 2025 — Qiming Venture Partners, HighLight Capital, Beida Fund, Linchuang Capital, Sanyi Capital, TruMed Healthcare, Shanzheng Innovation Investment
- Series B, Sep 24, 2024, $14M — Qiming Venture Partners
- Series B, Oct 31, 2023, $14M — Oriental Fortune Capital, Changshu Kaisheng Equity Investment Fund, Shanghai Tongrui Investment Management, Shanzheng Innovation Investment, Hefei Ruicheng Venture Capital Management
- Series A, Sep 27, 2022 — Yongshi Equity Investment Management
- Series A, Jan 5, 2021, $15M — Oriental Fortune Capital, Sangel Capital, New China Capital

## Investors

- Oriental Fortune Capital (https://capitalatlas.ai/funds/oriental-fortune-capital) — Series A, Series B
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Series A
- New China Capital (https://capitalatlas.ai/funds/new-china-capital) — Series A
- Yongshi Equity Investment Management (https://capitalatlas.ai/funds/yongshi-equity-investment-management) — Series A
- Changshu Kaisheng Equity Investment Fund — Series B
- Shanghai Tongrui Investment Management — Series B
- Shanzheng Innovation Investment — Series B, Series C
- Hefei Ruicheng Venture Capital Management (https://capitalatlas.ai/funds/hefei-ruicheng-venture-capital-management) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series C
- HighLight Capital (https://capitalatlas.ai/funds/highlight-capital) — Series C
- Beida Fund (https://capitalatlas.ai/funds/beida-fund) — Series C
- Linchuang Capital (https://capitalatlas.ai/funds/linchuang-capital) — Series C
- Sanyi Capital (https://capitalatlas.ai/funds/sanyi-capital) — Series C
- TruMed Healthcare — Series C